Comparison of Standard vs. Accelerated Corneal Crosslinking

Launched by PRICE VISION GROUP · Apr 19, 2019

Keywords

ClinConnect Summary

This clinical trial is studying two different methods of a treatment called corneal crosslinking, which is used for patients with progressive keratoconus or corneal ectasia. Keratoconus is a condition where the cornea (the front part of the eye) becomes thin and bulges outward, causing vision problems. The trial aims to compare the standard method of corneal crosslinking with a quicker, accelerated version to see which is more effective in helping patients.

To be eligible for this trial, participants should be between the ages of 36 and 52 and have a confirmed diagnosis of keratoconus or corneal ectasia, especially after having surgery for vision correction. However, some individuals may not be able to participate if they have certain eye conditions, insufficient corneal thickness, or a history of eye injuries that could complicate treatment. If you join the trial, you can expect to receive one of the two treatments and be monitored for how well it works. This study is currently recruiting participants, and it’s important for anyone considering joining to discuss it with their doctor to see if they meet the eligibility criteria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Documented keratoconus or ectasia after refractive surgery
• Exclusion Criteria:
• • Insufficient corneal thickness
• • Ocular condition that may predispose the eye to complications
• • History of chemical injury or delayed epithelial healing
• • Condition that would interfere with or prolong epithelial healing
• • Known sensitivity to treatment medications
• • Pregnancy